The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 14 rounds in the feed, most often at Series B and in Biotech.
Corporationnovartis.comRounds from 2018-08-10 to 2026-11-05
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Anaheim Bio Anaheim Bio is unlocking the power of small molecules to transform disease and improve patients' lives. | Series A Verified against 1 of 17 sources | $44.9M | 2026-11-05 | [ PART ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D+ |
| $67.4M |
| 2026-07-07 |
| [ PART ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series C Verified against 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $85M | 2026-06-30 | [ PART ] |
Sidewinder Therapeutics Sidewinder Therapeutics specializes in developing bispecific antibody-drug conjugates aimed at treating difficult cancers for patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $137M | 2026-04-08 | [ LEAD ] |
EpiBiologics They develop bispecific antibodies designed to selectively degrade disease-causing extracellular proteins. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $107M | 2026-01-08 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-11-17 | [ PART ] |
SpliceBio SpliceBio develops next-generation gene therapies using their proprietary Protein Splicing platform, targeting diseases caused by mutations in large genes. | Series B Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $135M | 2025-06-11 | [ PART ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D+ Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $38M | 2025-05-22 | [ PART ] |
Granite Bio Granitebio is a biotechnology company developing innovative therapies focusing on inflammatory, autoimmune, and fibrotic diseases with first-in-class antibodies. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $30M | 2025-04-24 | [ LEAD ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2023-08-23 | [ PART ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $123M | 2023-03-22 | [ PART ] |
SpliceBio SpliceBio develops next-generation gene therapies using their proprietary Protein Splicing platform, targeting diseases caused by mutations in large genes. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $56.9M | 2022-02-16 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $153M | 2021-07-27 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $84M | 2018-08-10 | [ PART ] |